Searched for
BIOCON MARGIN EXPANSION
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...- Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Biocon Q4 results: Net profit surges 153% at Rs 344 croreBiocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's bi...
- Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...
- Eris Lifesciences Q1 Results: Net dips 4.5% YoY at Rs 89 croreEris Lifesciences on Friday said its consolidated profit after tax declined by 4.5 per cent year on year to Rs 89 crore for the quarter end...
- Buy Biocon, target price Rs 266: Sharekhan by BNP ParibasBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 26389.19 Crore) operating in Pharmaceuticals secto...
- Biocon Q3 Results: Net profit rises 11% YoY to Rs 187 croreThe earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...
- Biocon reports 17% drop in net profit, Christiane Hamacher steps down as MD of Biocon Biologics“2020 has been one of the most challenging years for the world with an unprecedented pandemic impact on the global economy. We continue to ...
- Reduce Biocon, target price Rs 250: EdelweissThe stock is trading at 32 times FY22E EPS, which factors in the benefit from potential launches, but not the risks involved.
- Biocon Q2 net profit at Rs 216 croreConsolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration.
- Stock pick of week: Biocon is on fast track to growth, making it analysts' top betStrong annual results for 2018-19 including improvement in net profit, growth momentum in its biosimilars business and recent price correct...
- Hep C drugs will be a Rs 1,000-cr market; Cimivir-L will boost Biocon's virology biz: Kiran Mazumdar-Shaw"The market for Hepatitis C drugs is fairly large. There are high incidences of Hepatitis C in many parts of our country."
- Return ratios for Biocon to remain tepid; prefer Sun Pharma among pharma names: Mayuresh JoshiInvestors must adopt stock-specific approach as valuations have turned expensive on pharma counters, says Joshi in an interview to ET Now.
- Biocon Q4 profit zooms to Rs 81 croreBiotechnology major Biocon's net profit for the fourth quarter rose sharply after revenues increased and a forex loss of Rs 41.4 crore had ...
- Religare upholds 'Buy' on Biocon at Rs 542Religare Research has maintained a ‘buy’ on Biocon post its second quarter earnings for the September quarter. It has set a target price of...
Load More
